Not checkedNot checked for notices yet.

FDA efficiency for approval process of COVID-19 therapeutics

Christine Cassidy, Danielle Dever, Laura Stanbery and 3 more

Infectious Agents and Cancer · 2020

doi:10.1186/s13027-020-00338-z (opens in a new tab)

We email you when a new notice or a question about this paper appears.

References48

12.
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases · 2017
13.
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses · 2017
16.
Estimation of clinical trial success rates and related parameters · 2018
20.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
21.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020
25.
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · 2020
33.
Corrected
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV · 2020
41.
Cell entry mechanisms of SARS-CoV-2 · 2020
42.
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial · 2020

39 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.